Last reviewed · How we verify
Anti-GITR Agonistic Monoclonal Antibody BMS-986156 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-GITR Agonistic Monoclonal Antibody BMS-986156 (Anti-GITR Agonistic Monoclonal Antibody BMS-986156) — M.D. Anderson Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-GITR Agonistic Monoclonal Antibody BMS-986156 TARGET | Anti-GITR Agonistic Monoclonal Antibody BMS-986156 | M.D. Anderson Cancer Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156 CI watch — RSS
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156 CI watch — Atom
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156 CI watch — JSON
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156 alone — RSS
Cite this brief
Drug Landscape (2026). Anti-GITR Agonistic Monoclonal Antibody BMS-986156 — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-gitr-agonistic-monoclonal-antibody-bms-986156. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab